Novavax reports Q3 2026 revenue of $68 million
Company reported Q3 2026 revenue of $68 million. Investors should note the $125 million milestone from Sanofi and revised full-year revenue guidance.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed